0001493152-24-014604.txt : 20240415
0001493152-24-014604.hdr.sgml : 20240415
20240415154507
ACCESSION NUMBER: 0001493152-24-014604
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240411
FILED AS OF DATE: 20240415
DATE AS OF CHANGE: 20240415
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pershing Edward
CENTRAL INDEX KEY: 0001689739
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36457
FILM NUMBER: 24844533
MAIL ADDRESS:
STREET 1: 2220 SOUTHERLAND AVE
CITY: KNOXVILLE
STATE: TN
ZIP: 37919
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PROVECTUS BIOPHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000315545
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 900031917
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 S. GAY STREET
STREET 2: SUITE 1610
CITY: KNOXVILLE
STATE: TN
ZIP: 37929
BUSINESS PHONE: (866) 594-5999
MAIL ADDRESS:
STREET 1: 800 S. GAY STREET
STREET 2: SUITE 1610
CITY: KNOXVILLE
STATE: TN
ZIP: 37929
FORMER COMPANY:
FORMER CONFORMED NAME: PROVECTUS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20020417
FORMER COMPANY:
FORMER CONFORMED NAME: ZAMAGE DIGITAL IMAGING INC
DATE OF NAME CHANGE: 20011126
FORMER COMPANY:
FORMER CONFORMED NAME: SPM GROUP INC
DATE OF NAME CHANGE: 19920703
4
1
ownership.xml
X0508
4
2024-04-11
0
0000315545
PROVECTUS BIOPHARMACEUTICALS, INC.
PVCT
0001689739
Pershing Edward
800 S. GAY STREET, SUITE 1610
KNOXVILLE
TN
37929
1
0
0
0
0
8% Unsecured Convertible Promissory Note
2.862
2024-04-11
4
A
0
20000
0
A
2024-04-11
2025-04-11
Series D-1 Convertible Preferred Stock
6989
1810000
D
The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "Note") at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note. The Note was issued pursuant to the Issuer's 2022 Financing.
Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Preferred Stock.
/s/ Edward Pershing
2024-04-15